OncoMatch/Liver Cancer (HCC)/TP53

Liver Cancer (HCC)TP53 Clinical Trials

TP53 mutations occur in 15–30% of HCC and are among the most common somatic alterations in this cancer, often arising in the context of HBV-related hepatocarcinogenesis. TP53-mutant HCC is associated with aggressive biology and poor prognosis. Trials explore p53-reactivating agents, combination regimens targeting co-occurring vulnerabilities, and novel therapeutic strategies in TP53-altered advanced HCC.